PharmaTelevision - Merck & Co.: Merging With Schering-Plough and Future Plans

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Merck & Co.: Merging With Schering-Plough and Future Plans

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Pamela Demain, Executive Director, Corporate Licensing at Merck & Co. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss:

• The merger with Schering-Plough and its effect on structure

• How internal and external R&D is balanced at Merck

• The new out-licensing group

• Guidelines for out-licensing

• Merck's policy on purchasing biotechs

• How under-funding in biotechs could affect Merck's pipeline

• Option-based deals

• Relationships with Venture Capitalists

• Potential future deals

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The merger with Schering Plough and its effect on structure.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Barcelona at BioEurope. On this show I have Pamela Demain, who is Executive Director, Corporate Licensing at Merck , welcome to the show.

Pamela Demain:

Thank you.

Fintan Walton:

Pamela Demain, Merck has been in the news in 2009 for one very big reason it acquired Schering Plough or merged with Schering Plough and that must have had a significant effect on the corporation while so you wouldn't have done it, had to have some sort of repercussion particularly in an organizational point of view did that change the way licensing and the structure of licensing within Merck , did that change?

Pamela Demain:

The good news is that it hasn't changed which makes us very happy because we think we have a great licensing structure and process that we've put in place over the past 10-years. And it works very well probably one of the most efficient in the industry. We are getting more resources so if it has changed it's changed in a good way in that departments are expanding so we have more resources new more resources in all area of the licensing process and we are now financially stronger so that we can do more deals of strategic importance.

Fintan Walton:

So that the team, the team is the same there is some there is one change I think Mervyn Turner?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Pamela Demain

Executive Director

Pamela Demain is Executive Director, Corporate Licensing at Merck & Co., Inc. She has been at Merck & Co for twenty-five years. For twelve years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide. Prior to her current position, Ms.Pamela Demain was in charge of the Business Information & Research Group in the Worldwide Human Health Marketing area of Merck & Co providing strategic decision support for new and in-line products.

Merck & Co

Merck & Co ., Inc., also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The headquarters of the company is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. It was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co . was confiscated in 1917 during World War I and set up as an independent company. It is currently one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue. Schering Plough Schering Plough manufactures several pharmaceutical drugs, the most well-known of which are the allergy drugs Claritin and Clarinex, and through a collaboration with Merck & Co ., Vytorin, an anti-cholesterol drug.